Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower Kd...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interplay Between Acute Heart Failure and COPD in Patients Hospitalized for Dyspnea: Prognostic Insights From the PARADISE Cohort.

ESC heart failure·2026
Same author

Short- and Long-Term Mortality in Patients Hospitalized for Dyspnoea with Acute Heart Failure, Respiratory Infection, or Both: Insights from the PARADISE Cohort.

European journal of heart failure·2026
Same author

Proteomic phenotyping with machine learning for cardiovascular outcomes in haemodialysis: insights from the AURORA trial.

European heart journal. Digital health·2026
Same author

Comparative diagnostic performance of machine learning models and traditional scores for HFpEF in older adults.

European journal of heart failure·2026
Same author

Short and long-term prognosis of hospitalization for dyspnoea based on aetiology and hospitalization ward: insights from the PARADISE cohort.

European journal of heart failure·2026
Same author

Unsupervised machine learning for cardiovascular disease: A framework for future studies.

European journal of heart failure·2025

Related Experiment Video

Updated: May 10, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

Integrative relational machine-learning for understanding drug side-effect profiles.

Emmanuel Bresso, Renaud Grisoni, Gino Marchetti

    BMC Bioinformatics
    |June 28, 2013
    PubMed
    Summary
    This summary is machine-generated.

    This study introduces side-effect profiles (SEPs) by clustering drug side effects to identify common patterns. These profiles aid in predicting potential adverse drug reactions and improving drug development.

    More Related Videos

    A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
    07:40

    A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

    Published on: May 27, 2021

    Related Experiment Videos

    Last Updated: May 10, 2026

    Diagonal Method to Measure Synergy Among Any Number of Drugs
    12:08

    Diagonal Method to Measure Synergy Among Any Number of Drugs

    Published on: June 21, 2018

    A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
    07:40

    A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

    Published on: May 27, 2021

    Area of Science:

    • Pharmacology and Cheminformatics
    • Computational Drug Discovery

    Background:

    • Drug side effects are a major cause of clinical trial attrition and pose risks for marketed drugs.
    • Current research often overlooks the co-occurrence and redundancy of drug side effects.
    • Understanding complex side effect patterns is crucial for drug development and safety.

    Purpose of the Study:

    • To develop a method for identifying and characterizing recurring patterns of drug side effects.
    • To improve the prediction of drug side effects by analyzing their co-occurrence.
    • To reduce attrition rates in drug development by better understanding potential adverse events.

    Main Methods:

    • Collected drug annotations from SIDER and DrugBank databases.
    • Clustered individual side effect terms into term clusters (TCs) using semantic similarity.
    • Extracted maximal frequent itemsets to define side-effect profiles (SEPs) as shared TC combinations across drugs.
    • Applied decision-tree and inductive-logic programming methods to explore SEPs using integrated drug and target descriptors.

    Main Results:

    • Identified side-effect profiles (SEPs) representing combinations of TCs shared by multiple drugs.
    • Inductive-logic programming demonstrated superior performance over decision trees, leveraging background knowledge.
    • Discovered explicit rules characterizing drug-SEP associations by integrating chemical and biological data.
    • Models and theories are publicly accessible via a dedicated website.

    Conclusions:

    • Successfully extracted significant side effect profiles (SEPs) from drug-side effect data.
    • Integrated background knowledge with relational learning to discover explicit drug-SEP association rules.
    • Demonstrated the utility of these rules for predicting SEPs in new drug molecules.